QIAGEN partners with The Scientific Group to expand commercial presence in Africa
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the appointment of The Scientific Group, a South Afri…
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the appointment of The Scientific Group, a South Afri…
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute die Zulassung von PartoSure in den USA bekannt. Dabei…
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that a U.S. reference laboratory customer of i…
. Achieves Q1 2013 targets: Net sales of $303.6 million grow 3% CER on expansion in all regions; adjusted diluted EPS…
. QIAGEN exceeds Q4 and full-year 2012 targets: - Full-year 2012: Net sales advance 10% CER (+7% reported) to $1.…
. - Commercial launch of careHPV in China and other emerging markets will enable high-quality screening for prevention…
. - QIAGEN's cutting-edge ESEQuant Lateral Flow System will run Lepu Medical's tests for key cardiac biomarkers to deli…
. - Solid performance in second quarter of 2012: Net sales rise 9% (+14% CER) to $307.2 million on growth in all custom…
. - QIAGEN expands Point of Need portfolio with unique AmniSure® assay to detect rupture of fetal membranes (ROM) - che…
. - Point-of-Care Diagnostics Initiative is part of Grand Challenges in Global Health program funded by Bill & Melinda…